Finke J, Slanina J, Lange W, Dölken G
Department of Radiotherapy, University of Freiburg, Germany.
J Clin Oncol. 1993 Sep;11(9):1668-73. doi: 10.1200/JCO.1993.11.9.1668.
To determine the prevalence of circulating t(14;18)-positive cells in patients with long-term remission after radiation therapy for stage I and II follicular lymphoma.
Peripheral-blood mononuclear cells from 21 patients in continuous remission were examined by a two-step polymerase chain reaction (PCR) assay for the detection of cells carrying a t(14;18) translocation with a breakpoint within the major breakpoint region (MBR) or minor cluster region (mcr).
Follow-up duration was between 25 and 160 months, with a median of 6.5 years. Thirteen patients (62%) showed negative results on repetitive testing. Cells that were t(14;18)-positive were found in eight patients (38%), all carrying a breakpoint in the MBR. One patient relapsed in each group.
Circulating t(14;18)-positive cells can persist in a high percentage of follicular lymphoma patients in long-term complete remission (CR) after radiation treatment for stage I and II disease. The significance of minimal residual t(14;18)-positive cells with regard to the risk of relapse needs to be investigated in further prospective long-term studies.
确定I期和II期滤泡性淋巴瘤放疗后长期缓解患者循环中t(14;18)阳性细胞的患病率。
对21例持续缓解患者的外周血单个核细胞进行两步聚合酶链反应（PCR）检测，以检测携带t(14;18)易位且断点位于主要断点区域（MBR）或次要簇区域（mcr）的细胞。
随访时间为25至160个月，中位时间为6.5年。13例患者（62%）重复检测结果为阴性。8例患者（38%）检测到t(14;18)阳性细胞，所有细胞的断点均位于MBR。每组各有1例患者复发。
I期和II期滤泡性淋巴瘤患者放疗后长期完全缓解（CR）时，循环中t(14;18)阳性细胞可在相当比例的患者中持续存在。关于微小残留t(14;18)阳性细胞与复发风险的关系，需要进一步进行前瞻性长期研究。
